Published on

Urology – Prostate Cancer: Positive Surgical Margins Following Radical Prostatectomy

Definition, Risk Factors, Surgical Pathology, PSA Surveillance, Adjuvant and Salvage Radiotherapy, Prognosis, and Clinical Management

1. Definition and Clinical Overview

A positive surgical margin (PSM) following radical prostatectomy is defined by the presence of prostate cancer cells at the inked surgical resection surface of the prostatectomy specimen.

This indicates that malignant glands extend to the boundary of the tissue removed during surgery.

A positive margin may be described as:

  • Focal or extensive.
  • Unifocal or multifocal.
  • Located at the apex, posterolateral surface, bladder neck, or another anatomical site.

Clinical Significance

A PSM is associated with increased risk of:

  • Biochemical recurrence.
  • Local recurrence.
  • Subsequent cancer progression.

However, not all patients with positive margins develop recurrent prostate cancer.

Clinical Importance

A Positive Surgical Margin Is An Adverse Pathological Finding, But It Does Not Automatically Establish Residual Viable Cancer, Biochemical Recurrence, Or The Need For Immediate Additional Treatment.


2. Positive Versus Negative Surgical Margins

Positive Surgical Margin

Malignant cells are in direct contact with the inked resection surface.

Negative Surgical Margin

No malignant cells touch the inked surgical surface.

Tumour may be very close to the resection boundary without constituting a positive margin.

Important Principle

Cancer Close To The Surgical Margin Is Not The Same As Cancer At The Surgical Margin.

The relationship between tumour cells and the inked surface is the defining pathological criterion.


3. Surgical Margin Status and Pathological Stage

Surgical margin status must be distinguished from pathological tumour stage.

Organ-Confined Disease

pT2.

Cancer remains within the prostate.

A positive margin may still occur if the prostate is inadvertently incised during surgery.

Extraprostatic Extension

pT3a.

Cancer extends beyond the prostate gland.

The surgical margin may be positive or negative.

Seminal Vesicle Invasion

pT3b.

Cancer invades the seminal vesicles.

Margin status is independently assessed.

Clinical Importance

Extraprostatic Extension And Positive Surgical Margins Are Separate Pathological Findings.

Neither finding automatically proves the presence of the other.


4. Epidemiology

Historical Incidence in Organ-Confined Cancer

The original chapter reports:

5–27%.

Historical Incidence in Non-Organ-Confined Cancer

Approximately:

17–65%.

Clinical Interpretation

Positive surgical margins are more common when prostate cancer extends beyond the gland.

Important Qualification

These percentages represent heterogeneous historical studies.

Contemporary rates vary according to:

  • Patient selection.
  • Cancer risk category.
  • Pathological stage.
  • Surgical technique.
  • Surgeon experience.
  • Pathological specimen processing.


5. Risk Factors for Positive Surgical Margins

The original source identifies several important predictors.

Principal Factors

  • Higher preoperative PSA.
  • Higher clinical T stage.
  • Higher Gleason score.
  • Higher pathological T stage.
  • Surgeon experience.

Additional Clinical Considerations

  • Tumour location.
  • Tumour volume.
  • Extraprostatic extension.
  • Neurovascular bundle involvement.
  • Anatomical difficulty.

Clinical Importance

High-Grade Or Locally Advanced Prostate Cancer Increases The Risk Of A Positive Surgical Margin Because Complete Resection Becomes More Difficult.


6. Preoperative PSA

Higher PSA may suggest greater tumour burden.

Possible Associations

  • More extensive intraprostatic cancer.
  • Extraprostatic extension.
  • Seminal vesicle involvement.
  • Increased likelihood of incomplete resection.

Important Qualification

PSA alone cannot accurately predict surgical margin positivity.

It must be interpreted with:

  • MRI.
  • Biopsy Grade Group.
  • Clinical stage.
  • Other relevant factors.


7. Histological Grade

Higher Gleason scores are associated with greater biological aggressiveness.

Important Grade Groups

  • Grade Group 1: Gleason 3 + 3.
  • Grade Group 2: Gleason 3 + 4.
  • Grade Group 3: Gleason 4 + 3.
  • Grade Group 4: Gleason score 8.
  • Grade Group 5: Gleason scores 9–10.

Clinical Importance

High ISUP Grade Group Increases The Risk Of Adverse Pathological Features And May Increase The Clinical Consequences Of A Positive Surgical Margin.


8. Pathophysiology of Positive Surgical Margins

The original chapter identifies three principal mechanisms.

1. Tumour Extension to the Resection Boundary

Cancer extends beyond normal prostate tissue and reaches the surgical margin.

This may occur in locally advanced disease.

2. Iatrogenic Incision Into the Prostate

The surgeon inadvertently cuts through prostatic tissue containing malignant glands.

This can produce a positive margin even when the original tumour is otherwise organ-confined.

3. Specimen Manipulation or Pathological Artifact

Surgical handling, tissue disruption, or specimen-processing artifact can complicate margin interpretation.

Clinical Importance

A Positive Surgical Margin May Reflect True Tumour Extension, Surgical Incision Into Cancer, Or Occasionally Difficult Pathological Interpretation.


9. Extraprostatic Extension Versus Capsular Incision

Extraprostatic Extension

Cancer has invaded beyond the prostate into periprostatic tissues.

Iatrogenic Capsular Incision

Surgical dissection enters the prostate and exposes malignant glands at the specimen surface.

Clinical Significance

An iatrogenic positive margin may occur without true extraprostatic extension.

Important Principle

Tumour at the Margin Does Not Automatically Indicate pT3 Disease.


10. Prevention of Positive Surgical Margins

Main Surgical Principle

Achieve complete cancer removal while preserving surrounding structures when oncologically appropriate.

Important Surgical Considerations

  • Accurate preoperative assessment.
  • Appropriate dissection planes.
  • Avoidance of unnecessary capsular incision.
  • Careful apical dissection.
  • Careful posterolateral dissection.
  • Appropriate nerve-sparing selection.

Clinical Importance

Surgical Margin Prevention Requires Balancing Oncological Clearance Against Preservation Of Urinary Continence And Erectile Function.


11. Surgeon Experience

The original chapter emphasizes surgical experience as an important determinant of margin positivity.

Possible Benefits of Greater Experience

  • Better anatomical identification.
  • More consistent dissection planes.
  • Improved cancer clearance.
  • Appropriate nerve-sparing decisions.
  • Reduced technical errors.

Clinical Importance

Surgeon Experience And Procedure Quality Are Important Factors In Radical Prostatectomy Outcomes.


12. Surgical Approach

The historical source describes:

  • Open radical prostatectomy.
  • Laparoscopic radical prostatectomy.
  • Robot-assisted radical prostatectomy.

Historical Finding

No clear universal advantage of one approach in preventing positive surgical margins.

Contemporary Interpretation

Outcomes depend on:

  • Case complexity.
  • Surgeon experience.
  • Surgical technique.
  • Patient and tumour characteristics.

Clinical Importance

The Choice Of Surgical Approach Should Be Based On Oncological Safety And Surgical Expertise Rather Than Assuming One Technique Always Produces Fewer Positive Margins.


13. Important Anatomical Sites

The original chapter identifies three common sites of PSM.

Prostatic Apex

A frequent location.

Posterolateral Prostate

Includes regions adjacent to the neurovascular bundles.

Bladder Neck

Another important anatomical site.

Clinical Importance

The Apex, Posterolateral Surface, And Bladder Neck Are Important Locations For Positive Surgical Margins Following Radical Prostatectomy.


14. Apical Positive Surgical Margins

Anatomical Consideration

The prostatic apex does not have a well-defined capsule comparable to other regions of the gland.

This makes dissection and pathological interpretation more challenging.

Possible Causes

  • Incision into the apical prostate.
  • Cancer reaching the resection surface.
  • Complex anatomical boundaries.
  • Tissue processing artifacts.

Important Qualification

The absence of a well-defined capsule does not mean that every apical positive margin is artifactual.

If Cancer Cells Touch The Properly Inked Surgical Margin At The Apex, The Margin Is Positive.


15. Posterolateral Positive Margins

Anatomical Relationship

The posterolateral prostate lies close to important neurovascular structures.

Surgical Challenge

The surgeon must balance:

  • Complete cancer excision.
  • Nerve preservation.
  • Avoidance of capsular incision.

Clinical Importance

Posterolateral Margins Are Particularly Relevant When Planning Nerve-Sparing Surgery In Patients With Suspected Extraprostatic Extension.


16. Bladder Neck Positive Margins

Anatomical Consideration

The prostate base lies adjacent to the urinary bladder.

Clinical Importance

Dissection in this region requires preservation of urinary anatomy while obtaining adequate cancer clearance.

Important Staging Distinction

Microscopic bladder neck invasion is classified as pT3a under contemporary pathological staging.

A bladder neck positive margin and microscopic bladder neck invasion should be documented separately when appropriate.


17. Classification of Positive Margins

Margin reporting may include several characteristics.

Focal Versus Extensive

Describes the amount of tumour at the resection surface.

Unifocal Versus Multifocal

Describes whether one or several separate areas are involved.

Anatomical Location

Identifies the specific site.

Gleason Pattern at the Margin

Provides information about the aggressiveness of cancer contacting the resection surface.


18. Positive Margin Length

Contemporary Pathological Assessment

The linear extent of involved margin may be measured in millimetres.

Commonly Studied Threshold

3 mm.

Studies have compared:

  • Margin length below 3 mm.
  • Margin length of 3 mm or greater.

Clinical Significance

Longer positive margins are generally associated with increased risk of biochemical recurrence.

Important Qualification

Different pathology protocols and studies may use different definitions for focal and extensive involvement.

Clinical Importance

The Length Of A Positive Surgical Margin May Provide Independent Prognostic Information Beyond Simple Positive-Versus-Negative Status.


19. Multifocal Positive Margins

Definition

Cancer reaches the resection surface at more than one separate location.

Potential Significance

May indicate greater overall margin involvement.

Clinical Importance

Multifocality should be considered together with:

  • Margin length.
  • Grade Group.
  • Pathological stage.
  • PSA response.

It should not be interpreted in isolation.


20. Gleason Pattern at the Positive Margin

Clinical Role

The cancer grade at the positive margin may influence recurrence risk.

Important Considerations

  • Gleason pattern 3.
  • Gleason pattern 4.
  • Gleason pattern 5.

Clinical Importance

A High-Grade Positive Margin May Be More Concerning Than A Margin Involving Only Lower-Grade Cancer.

Contemporary pathology guidance supports reporting the highest Gleason pattern at the positive margin when assessable.


21. Clinical History After Radical Prostatectomy

Important information includes:

  • Preoperative PSA.
  • Original clinical stage.
  • Biopsy Gleason score.
  • Date of surgery.
  • Surgical approach.
  • Final pathological stage.
  • Margin location and extent.
  • Nodal status.
  • Postoperative continence.
  • Erectile function.

Clinical Importance

Postoperative management depends on the entire pathological and clinical profile, not solely on the margin report.


22. Physical Examination

Digital Rectal Examination

The historical source notes that routine DRE may add little in patients with undetectable PSA after radical prostatectomy.

Contemporary Principle

Physical examination should be based on symptoms and clinical suspicion.

Clinical Importance

A Normal Postoperative DRE Does Not Exclude Microscopic Cancer Recurrence, And Routine DRE Is Not A Substitute For PSA Surveillance.


23. Postoperative PSA Assessment

Expected PSA Response

After complete prostate removal, PSA should generally decline to an undetectable or extremely low value.

Usual Timing

Approximately 6–8 weeks after surgery.

Main Clinical Patterns

  1. Undetectable PSA.
  2. Persistent detectable PSA.
  3. Initially undetectable PSA followed by a subsequent rise.

Clinical Importance

PSA Response Is Critical For Determining Whether A Patient With Positive Margins Requires Monitoring Or Further Treatment.


24. Biochemical Recurrence

Conventional Definition

Following radical prostatectomy:

PSA ≥0.2 ng/mL with a confirmatory second measurement.

Unit Correction

The historical source incorrectly describes the threshold using ng/dL.

The Correct PSA Unit Is ng/mL.

Clinical Importance

A confirmed rising PSA following surgery suggests persistent or recurrent PSA-producing tissue.

Important Qualification

Selected high-risk patients may benefit from assessment or salvage treatment before PSA reaches the conventional biochemical recurrence threshold.


25. Historical Biochemical Recurrence Risk

The original chapter reports that patients with PSM have an approximately:

25–40% Chance Of Subsequent Biochemical Recurrence.

Important Qualification

This is a historical estimate and varies according to:

  • Grade Group.
  • Pathological stage.
  • Margin length.
  • Margin location.
  • Nodal status.
  • PSA persistence.
  • Duration of follow-up.

Clinical Importance

Most Patients With Positive Surgical Margins In The Historical Estimates Did Not Develop Biochemical Recurrence During The Studied Follow-Up.


26. Positive Margins Without PSA Recurrence

A patient may have:

  • pT2 or pT3 prostate cancer.
  • One or more positive surgical margins.
  • Undetectable postoperative PSA.
  • No subsequent biochemical recurrence.

Possible Explanations

  • No surviving viable tumour at the surgical bed.
  • Small residual cancer burden eliminated by local tissue responses.
  • Indolent residual disease below clinical detection.
  • Variation in pathological margin interpretation.

Important Principle

A Positive Surgical Margin Should Prompt Risk Assessment And Follow-Up, Not An Automatic Diagnosis Of Recurrent Cancer.


27. Imaging After Radical Prostatectomy

Historical Recommendation

No additional imaging is necessary solely because a positive margin is identified.

Contemporary Principle

Routine restaging imaging is generally unnecessary when:

  • PSA remains undetectable.
  • The patient is asymptomatic.
  • There is no other reason to suspect active disease.

Clinical Importance

Margin Positivity Alone Is Not An Indication For Routine Bone Scan, CT, Or PSMA PET/CT.


28. Imaging When Recurrence Is Suspected

Historical Investigations

  • Bone scintigraphy.
  • Pelvic MRI.
  • CT abdomen and pelvis.
  • ProstaScint.

Contemporary Investigations

  • PSMA PET/CT.
  • Pelvic MRI.
  • Other imaging according to the suspected extent of disease.

Clinical Importance

PSMA PET/CT may detect:

  • Prostate-bed recurrence.
  • Pelvic nodal metastases.
  • Distant metastases.

Important Limitation

Microscopic cancer may remain undetected at low PSA concentrations.


29. Negative PSMA PET and Salvage Radiotherapy

A negative PSMA PET/CT does not exclude microscopic disease in the prostate bed.

Contemporary Principle

A Negative PSMA PET Scan Should Not Be Used As The Sole Reason To Withhold Otherwise Indicated Early Salvage Radiotherapy.

This is particularly important in patients with:

  • Confirmed rising PSA.
  • Favorable opportunity for curative salvage.
  • High-risk pathological features.


30. Role of Prostate Bed Biopsy

The historical source states that no routine biopsy is required solely for a positive surgical margin.

Clinical Importance

The Diagnosis Of A Positive Margin Is Established From The Original Radical Prostatectomy Specimen.

Prostate bed biopsy is not routinely necessary before standard early salvage radiotherapy.

Targeted biopsy may be considered if a suspicious lesion requires histological clarification.


31. Differential Diagnosis

Important possibilities include:

True Positive Surgical Margin

Cancer directly contacts the resection surface.

Iatrogenic Prostatic Incision

Surgical entry into cancer-containing prostatic tissue.

Extraprostatic Extension

Cancer extends beyond the gland.

Pathological Artifact

Tissue distortion or processing-related difficulty in margin interpretation.

Biochemical Recurrence

Rising PSA indicating possible persistent or recurrent cancer.

Important Principle

Positive margin status, extraprostatic extension, and biochemical recurrence are related but distinct concepts.


32. General Treatment Principles

Management depends on:

  1. Postoperative PSA.
  2. Final Grade Group.
  3. Pathological T stage.
  4. Surgical margin extent.
  5. Seminal vesicle invasion.
  6. Lymph node status.
  7. PSA doubling time if recurrence develops.
  8. Life expectancy.
  9. Postoperative functional recovery.
  10. Patient preferences.

Main Treatment Strategies

  • PSA surveillance.
  • Adjuvant radiotherapy in selected high-risk patients.
  • Early salvage radiotherapy when PSA rises.
  • ADT with salvage radiotherapy when indicated.

Clinical Importance

The Central Treatment Decision Is Whether Immediate Radiation Offers Sufficient Benefit To Justify Its Toxicity Or Whether Close Monitoring With Early Salvage Radiation Is Preferable.


33. Observation and PSA Surveillance

Appropriate Clinical Context

Patients with:

  • Undetectable postoperative PSA.
  • Positive surgical margins.
  • No other compelling indication for immediate treatment.

Main Requirements

  • Regular PSA monitoring.
  • Review of pathological risk.
  • Early reassessment if PSA rises.
  • Access to timely salvage treatment when needed.

Clinical Importance

Observation With Early Salvage Radiotherapy Is An Evidence-Based Strategy For Many Patients With Positive Margins And Undetectable PSA.


34. Adjuvant Radiotherapy

Definition

Radiotherapy delivered after radical prostatectomy while PSA remains undetectable, primarily because pathological findings predict a higher recurrence risk.

Historical Radiotherapy Techniques

  • Three-dimensional conformal radiotherapy.
  • Intensity-modulated radiotherapy.

Historical Dose

Approximately:

64–65 Gy.

Important Qualification

Dose and fractionation are selected according to contemporary radiotherapy planning rather than a single universal historical prescription.


35. Historical Benefits of Adjuvant Radiotherapy

The original chapter reports that adjuvant radiotherapy reduces:

  • Biochemical recurrence.
  • Local recurrence.
  • Clinical progression.

Important Uncertainty in the Historical Source

The effect on:

  • Distant metastases.
  • Prostate cancer-specific mortality.
  • Overall survival.

Was less consistently established across trials.

Clinical Importance

Adjuvant Radiotherapy Improves Some Cancer-Control Outcomes In Patients With Adverse Pathology, But The Magnitude Of Benefit Must Be Balanced Against Overtreatment.


36. Why Immediate Adjuvant Radiotherapy May Cause Overtreatment

Many patients with positive margins never experience biochemical recurrence.

Potential Consequence

Immediate radiation may expose these patients to toxicity without providing an individual survival benefit.

Important Toxicities

  • Urinary incontinence.
  • Irritative urinary symptoms.
  • Urethral stricture.
  • Rectal toxicity.
  • Erectile dysfunction.

Clinical Importance

Avoiding Unnecessary Radiation Is An Important Goal In Contemporary Postprostatectomy Management.


37. Adjuvant Versus Early Salvage Radiotherapy

Adjuvant Radiotherapy

Given before biochemical recurrence.

Early Salvage Radiotherapy

Given when postoperative PSA shows a convincing rise.

Major Contemporary Trials

  • RADICALS-RT.
  • RAVES.
  • GETUG-AFU 17.

Clinical Question

Does routine adjuvant radiation provide better cancer outcomes than close monitoring followed by early salvage radiation?


38. ARTISTIC Meta-Analysis

Study Population

Approximately:

2,153 patients.

Five-Year Event-Free Survival

  • Adjuvant radiotherapy: 89%.
  • Early salvage strategy: 88%.

Main Finding

No clear event-free survival advantage from routine adjuvant radiotherapy in the overall studied population.

Clinical Interpretation

An early salvage policy can spare some patients unnecessary radiation and its adverse effects.

Clinical Importance

For Many Patients With Adverse Postprostatectomy Pathology, Early Salvage Radiotherapy Is Preferred Over Routine Immediate Adjuvant Radiotherapy.


39. Selected Patients Who May Still Benefit From Adjuvant Radiotherapy

Contemporary EAU guidance recommends offering adjuvant radiation in selected patients with:

  • pN0 disease.
  • pT3 disease.
  • ISUP Grade Group 4–5.
  • With or without positive surgical margins.

Important Qualification

A Positive Surgical Margin Alone Is Not A Universal Indication For Adjuvant Radiotherapy.

Patients with multiple adverse features may have a greater potential benefit from immediate postoperative treatment.


40. Early Salvage Radiotherapy

Definition

Radiotherapy delivered after biochemical evidence of persistent or recurrent prostate cancer.

Main Target

Prostate bed.

Additional Possible Target

Pelvic lymph nodes in selected patients.

Clinical Objective

Eradicate microscopic residual cancer before clinically detectable progression develops.


41. Optimal PSA Level for Salvage Radiotherapy

The effectiveness of salvage radiation generally decreases as PSA rises.

Current AUA Recommendation

Deliver indicated salvage radiotherapy when PSA is:

≤0.5 ng/mL.

High-Risk Patients

Treatment may be considered at PSA:

Below 0.2 ng/mL

when the rising trend is confirmed.

Clinical Importance

Early Salvage Radiotherapy Should Not Be Unnecessarily Delayed Until PSA Reaches A High Level.


42. Prognostic Factors for Salvage Radiotherapy Response

Important variables include:

  • PSA before radiation.
  • PSA doubling time.
  • ISUP Grade Group.
  • Pathological stage.
  • Seminal vesicle invasion.
  • Surgical margins.
  • Time from prostatectomy to recurrence.
  • Presence of regional or distant disease.

Clinical Importance

Lower PSA At Salvage Treatment And Favorable Disease Biology Are Associated With Better Salvage Outcomes.


43. Androgen-Deprivation Therapy With Salvage Radiation

Historical Source

The chapter describes RTOG 9601 as an ongoing trial.

Contemporary Status

The trial has been completed, with long-term results published.

Main Question

Does the addition of long-term androgen receptor blockade improve outcomes following salvage radiotherapy?


44. RTOG 9601 Trial

Treatment Comparison

  • Salvage radiotherapy alone.
  • Salvage radiotherapy plus 24 months of bicalutamide.

Important Long-Term Outcomes

At approximately 12 years:

Overall Survival

  • Bicalutamide group: 76.3%.
  • Control group: 71.3%.

Distant Metastases

  • Bicalutamide group: 14.5%.
  • Control group: 23.0%.

Clinical Importance

The Trial Demonstrated That Adding Long-Term Antiandrogen Treatment To Salvage Radiotherapy Can Improve Important Oncological Outcomes In Selected Patients.


45. Important RTOG 9601 Subgroup Finding

Subsequent analyses examined whether benefit differed according to PSA before salvage radiation.

Higher PSA

Patients with higher PSA appeared more likely to benefit from prolonged antiandrogen therapy.

Very Low PSA

Patients treated at PSA ≤0.6 ng/mL did not demonstrate an overall survival improvement from two years of bicalutamide in the relevant secondary analysis.

Additional treatment-related harms were observed.

Clinical Importance

Long-Term ADT Should Not Be Added Automatically To Every Patient Receiving Very Early Salvage Radiotherapy.

The treatment decision must account for PSA, risk factors, comorbidities, and the specific hormonal regimen.


46. RADICALS and Subsequent Evidence

Historical Source

The RADICALS trial was ongoing when the chapter was written.

Contemporary Findings

Later evidence supports using early salvage radiation rather than routine immediate adjuvant treatment for many patients.

Additional Randomized Evidence

Trials including GETUG-AFU 16 and SPPORT support adding ADT and, in selected patients, pelvic lymph node radiotherapy to improve progression outcomes.

Clinical Importance

Both Radiotherapy Timing And The Selective Use Of Hormonal Treatment Have Changed Substantially Since The Original Chapter Was Published.


47. Contemporary Indications for ADT With Salvage Radiotherapy

AUA guidance recommends offering ADT with salvage radiotherapy when high-risk recurrence features are present.

Important Examples

  • PSA approximately 0.7 ng/mL or greater before salvage treatment.
  • ISUP Grade Group 4–5.
  • PSA doubling time ≤6 months.
  • Persistent postoperative PSA.
  • Seminal vesicle involvement.

Clinical Importance

High-Risk Biochemical Recurrence May Require Combined Salvage Radiotherapy And Hormonal Treatment Rather Than Radiation Alone.


48. Duration of ADT With Salvage Radiotherapy

Standard Minimum

When ADT is prescribed with salvage radiation:

At least 4–6 months.

Selected High-Risk Patients

Treatment may extend to:

18–24 months.

Important Qualification

Longer treatment increases the risk of systemic adverse effects.

Clinical Importance

ADT Duration Should Be Individualized According To Oncological Risk And Expected Treatment Toxicity.


49. Patients Who May Receive Salvage Radiation Without ADT

In patients without significant high-risk features, radiation alone may be appropriate.

Potential Favorable Features

  • Low PSA.
  • Slow PSA doubling time.
  • Lower Grade Group.
  • No seminal vesicle invasion.
  • No other major adverse recurrence characteristics.

Clinical Importance

Salvage Radiotherapy Without ADT Remains A Reasonable Option For Selected Lower-Risk Patients.


50. Genomic Classifiers

Historical Source

The chapter describes emerging genomic classifiers for estimating recurrence risk and selecting postoperative radiotherapy.

Contemporary Role

Selected genomic classifiers may contribute to:

  • Estimating metastatic risk.
  • Risk stratification.
  • Shared treatment decision-making.

Important Qualification

A genomic classifier should not independently determine adjuvant versus salvage treatment without consideration of conventional clinical findings.

Clinical Importance

Genomic Testing May Refine Prognosis But Does Not Replace PSA Surveillance, Pathology, Or Guideline-Based Treatment Selection.


51. Prognosis

A positive surgical margin is associated with a higher probability of biochemical recurrence than a negative margin.

However, prognosis depends on multiple factors.

Important Prognostic Variables

  • Gleason score.
  • ISUP Grade Group.
  • Pathological stage.
  • Seminal vesicle invasion.
  • Margin length.
  • Multifocality.
  • Gleason pattern at margin.
  • Nodal status.
  • Postoperative PSA.
  • PSA doubling time.

Clinical Importance

Not All Positive Surgical Margins Have The Same Prognostic Significance.


52. Biochemical Recurrence Versus Metastatic Progression

Biochemical Recurrence

An increase in PSA suggesting cancer activity.

Clinical Recurrence

Detectable local or regional tumour.

Metastatic Progression

Cancer identified outside the primary prostate region.

Important Principle

Biochemical Recurrence Does Not Automatically Mean That Distant Metastases Are Present Or That Prostate Cancer-Specific Death Is Inevitable.


53. Postoperative Prediction Tools

The historical source mentions nomograms such as those developed at Memorial Sloan Kettering Cancer Center.

Clinical Applications

Estimate:

  • Probability of recurrence.
  • Risk of disease progression.
  • Potential treatment benefit.

Important Qualification

Current, validated models should be selected whenever such tools are used clinically.


54. Complications of Radiotherapy

The original chapter reports a broad range of radiation toxicities.

Historical Acute Grade 1–2 Toxicity

Up to:

45%.

Historical Acute Grade 3–4 Toxicity

Up to:

20%.

Historical Late Toxicity

Up to:

28%.

Important Qualification

These are historical study figures with varying grading criteria and treatment techniques.

They should not be presented as expected modern toxicity rates.


55. Genitourinary Radiation Toxicity

Potential complications include:

  • Dysuria.
  • Urinary frequency.
  • Urgency.
  • Hematuria.
  • Radiation cystitis.
  • Urinary incontinence.
  • Urethral stricture.
  • Vesicourethral anastomotic narrowing.

Clinical Importance

Postoperative Radiotherapy May Worsen Urinary Function, Particularly In Patients With Pre-Existing Postprostatectomy Incontinence.


56. Gastrointestinal Radiation Toxicity

Important Complications

  • Radiation proctitis.
  • Rectal discomfort.
  • Rectal bleeding.
  • Bowel urgency.
  • Diarrhea.
  • Rare severe rectal injury.

Clinical Importance

Modern radiation planning aims to reduce the dose delivered to the rectum and other surrounding structures.


57. Sexual Function After Treatment

Radical Prostatectomy

May impair erectile function because of neurovascular injury.

Postoperative Radiotherapy

May contribute to further erectile deterioration.

ADT

May cause:

  • Reduced libido.
  • Erectile dysfunction.
  • Sexual dissatisfaction.

Clinical Importance

Postoperative Management Should Consider Both Cancer Control And Long-Term Sexual Function.


58. Follow-Up After Radical Prostatectomy

Historical Source Schedule

PSA approximately:

Every 3–6 months for the first 3–5 years.

Then:

Annually.

Contemporary EAU Framework

For patients after curative treatment:

  • PSA approximately every six months during the first three years.
  • Annually thereafter.

Important Qualification

Patients with positive margins and high-risk pathological findings may require more frequent assessments.


59. Monitoring During Observation

Main Investigations

  • Serial PSA.
  • PSA doubling time if a rise develops.
  • Clinical review.
  • Assessment of urinary and sexual function.

Imaging

Performed when it may change management.

Clinical Importance

Close Surveillance Is Essential When A Patient With Positive Surgical Margins Does Not Receive Immediate Adjuvant Radiation.


60. Follow-Up After Salvage Radiotherapy

Monitor:

  • PSA response.
  • Evidence of further recurrence.
  • Urinary continence.
  • Bowel symptoms.
  • Erectile function.
  • Radiation-related adverse effects.

During ADT

Additional assessment may include:

  • Serum testosterone.
  • Bone health.
  • Metabolic health.
  • Cardiovascular risk.
  • Treatment tolerability.


61. Practical Clinical Management Pathway

Patient With Positive Margin and Undetectable PSA

  1. Review final pathology.
  2. Determine Grade Group and pathological stage.
  3. Assess margin extent and location.
  4. Assess additional adverse features.
  5. Discuss observation versus adjuvant radiation.
  6. For most appropriate patients, continue PSA surveillance with a plan for early salvage treatment if required.

Patient With Positive Margin and Persistent PSA

  1. Confirm PSA persistence.
  2. Review pathological risk.
  3. Consider PSMA PET/CT if findings will affect management.
  4. Assess suitability for salvage radiotherapy.
  5. Consider ADT according to risk.

Patient With Positive Margin and Rising PSA After an Initial Undetectable Result

  1. Confirm the PSA trend.
  2. Estimate PSA doubling time.
  3. Review initial cancer pathology.
  4. Perform restaging imaging when appropriate.
  5. Offer early salvage radiotherapy when indicated.
  6. Add hormonal treatment in selected high-risk patients.


62. Clinical and Surgical Pearls

Margin Definition

  • A Positive Margin Means Tumour Cells Touch the Inked Surgical Surface.
  • Margin status is independent of pathological T stage.
  • A close negative margin is not positive.

Anatomical Sites

  • Prostatic apex.
  • Posterolateral surface.
  • Bladder neck.

Surgical Technique

  • Avoid unnecessary capsular incision.
  • Preserve appropriate anatomical dissection planes.
  • Select nerve sparing according to tumour extent.
  • Surgeon experience is important.

Pathology

  • Report margin location.
  • Report focality and extent.
  • Report Gleason pattern at the margin when possible.
  • Distinguish tumour extension from iatrogenic incision.

Prognosis

  • Positive margins increase biochemical recurrence risk.
  • Most patients in many historical cohorts do not recur.
  • Margin length and grade provide additional information.
  • PSA response is essential for postoperative risk assessment.

Radiotherapy

  • Routine adjuvant radiation is not necessary for every patient with a positive margin.
  • Early salvage radiotherapy is appropriate for many patients.
  • Selected very-high-risk patients may be offered adjuvant radiation.
  • Salvage treatment is generally more effective at lower PSA.

ADT

  • Offer ADT with salvage radiation for appropriately selected high-risk patients.
  • Low-risk patients may receive radiation alone.
  • Long-term hormonal treatment should not be added indiscriminately.


63. Essential Examination Principles

1. Define Positive Surgical Margin

Cancer cells directly contacting the inked prostatectomy specimen surface.

2. Distinguish Positive Margin From Extraprostatic Extension

Positive margins occur in both pT2 and pT3 disease.

3. Know the Common Sites

Apex, posterolateral region, and bladder neck.

4. Understand the Apex

The absence of a well-defined capsule makes dissection difficult but does not automatically make a positive margin artifactual.

5. Know the Historical PSM Incidence

Approximately 5–27% in organ-confined cancer and 17–65% in non-organ-confined disease.

6. Know the Historical Recurrence Risk

Approximately 25–40% following a positive margin.

7. Understand Margin Extent

Length and multifocality may influence recurrence risk.

8. Know the Correct PSA Unit

ng/mL.

9. Know the Conventional BCR Definition

Confirmed PSA of at least 0.2 ng/mL after radical prostatectomy.

10. Remember That Margin Positivity Alone Does Not Require Imaging

Imaging is guided by PSA and clinical risk.

11. Understand Adjuvant Versus Salvage Radiation

Adjuvant radiation is given before recurrence; salvage radiation follows evidence of persistent or recurrent disease.

12. Know the ARTISTIC Findings

No clear five-year event-free survival benefit from routine adjuvant radiation compared with early salvage in the overall studied population.

13. Treat at a Low PSA When Salvage Is Indicated

AUA guidance recommends salvage radiation at PSA ≤0.5 ng/mL.

14. Recognize Very-High-Risk Pathology

Selected pT3, Grade Group 4–5, pN0 patients may be offered adjuvant radiation.

15. Understand RTOG 9601

Adding 24 months of bicalutamide improved long-term outcomes in the overall trial population, but benefit and harm differed according to PSA and risk.

16. Know When to Add ADT

High-grade disease, rapid PSA doubling, persistent PSA, seminal vesicle involvement, and higher presalvage PSA are important indications.

17. Counsel About Treatment Toxicity

Urinary continence, bowel symptoms, erectile function, and systemic hormonal effects.

18. Maintain Long-Term PSA Surveillance

A positive margin warrants monitoring even when PSA is initially undetectable.


64. Historical Recommendations Versus Contemporary Practice

Positive Margin Definition

The historical definition remains valid.

The modern requirement is direct malignant cell contact with the inked surgical surface.

Histological Margin Features

The source emphasizes that location, extent, and number of positive margins did not improve risk prediction substantially in one historical study.

Contemporary pathological evidence supports the prognostic value of margin length and grade in selected analyses.

Historical Incidence

The ranges reflect older cohorts and should not be treated as contemporary universal incidence estimates.

Routine Imaging

The source recommends no additional imaging solely for a positive margin.

This principle remains appropriate when PSA is undetectable and the patient is asymptomatic.

ProstaScint

The historical source describes ProstaScint for selected patients with rising PSA.

Modern PSMA PET/CT has largely replaced this older molecular imaging technique.

Immediate Adjuvant Radiation

The source emphasizes improved biochemical control from adjuvant radiotherapy.

Current randomized evidence supports early salvage treatment for many patients.

RADICALS Trial

The original source describes results as pending.

The trial has since been completed and contributes to the evidence supporting early salvage treatment.

RTOG 9601

The original source describes preliminary results.

Long-term results demonstrate benefit from ADT added to salvage radiation in the overall study population, with important variation in treatment benefit according to PSA and patient risk.

Radiation Dose

The source describes 64–65 Gy as a typical dose.

Contemporary radiotherapy is prescribed according to individual planning and guideline recommendations.

Radiation Toxicity

The original rates are historical and should not be applied directly to modern IMRT/VMAT treatment.

Genomic Classifiers

These may provide additional risk information but should not independently determine postoperative treatment.


65. Historical Diagnostic Codes

ICD-9

185

Malignant neoplasm of prostate.

V45.77

Acquired absence of genital organ.

ICD-10 Codes Listed in the Source

C61

Malignant neoplasm of prostate.

Z90.79

Acquired absence of other genital organs.

Coding Qualification

These codes are retained from the historical chapter.

A positive surgical margin is a pathological finding and does not independently establish active recurrent cancer.

Clinical coding should reflect the documented malignancy status and applicable coding rules.


Final Urological Revision Summary

Positive surgical margins after radical prostatectomy indicate malignant cells at the inked surgical resection surface and are associated with an increased risk of biochemical recurrence.

Main Risk Factors

  • High preoperative PSA.
  • Advanced clinical stage.
  • High Gleason score.
  • Advanced pathological stage.
  • Extraprostatic extension.
  • Surgeon experience.

Main Anatomical Sites

  • Apex.
  • Posterolateral prostate.
  • Bladder neck.

Main Pathological Features

  • Focal versus extensive.
  • Unifocal versus multifocal.
  • Margin length.
  • Anatomical location.
  • Gleason pattern at margin.

Important Distinctions

Positive Surgical Margin

Cancer reaches the resection surface.

Extraprostatic Extension

Cancer extends beyond the prostate.

PSA Persistence

PSA fails to reach an undetectable level after surgery.

Biochemical Recurrence

A subsequent confirmed PSA rise after prostatectomy.

Main Postoperative Management

Positive Margin With Undetectable PSA

  • Review pathology and recurrence risk.
  • Regular PSA surveillance.
  • Consider adjuvant radiation in selected very-high-risk patients.
  • Plan early salvage treatment if biochemical recurrence develops.

Persistent or Rising PSA

  • Confirm PSA trend.
  • Review PSA doubling time.
  • Consider appropriate imaging.
  • Offer early salvage radiation when indicated.
  • Add ADT selectively according to recurrence risk.

Important Contemporary Recommendations

  • Avoid routine adjuvant radiation solely because the margin is positive.
  • Offer early salvage radiotherapy at low PSA when clinically appropriate.
  • Do not withhold necessary salvage radiotherapy solely because PSMA PET is negative.
  • Add ADT in patients with high-risk features.
  • Balance oncological benefit against urinary, sexual, bowel, and hormonal treatment complications.

Follow-Up Priorities

  • Serial PSA.
  • PSA doubling time when recurrence develops.
  • Urinary continence.
  • Erectile function.
  • Bowel symptoms following radiation.
  • ADT adverse effects when applicable.
  • Imaging when clinically indicated.

The Central Urological Objective Is To Recognize The Prognostic Importance Of Positive Surgical Margins Without Assuming That Every Patient Has Residual Cancer, Use PSA Surveillance To Identify Recurrence Early, Select Adjuvant Radiation Only For Appropriate High-Risk Patients, Deliver Early Salvage Treatment When Indicated, And Preserve Long-Term Urinary, Sexual, And Overall Quality Of Life.

 

Image description
0 Comments